Skip to main content

Table 1 Absolute outcome and prevented cases for different ages at vaccination in the base case scenario

From: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

 

60 years

65 years

70 years

75 years

80 years

Before vaccination:

     

Cases HZ

26845

15513

11093

7630

4769

Cases PHN

4639

2936

2351

1857

1370

Hospitalization

320

205

163

128

89

1 day visit hospital

1102

683

515

363

210

Deaths

30.7

20.9

18.6

17.6

16.5

Direct costs*

€2217577

€1527388

€1306022

€1100313

€847884

Indirect costs*

€1241555

€0

€0

€0

€0

QALYs lost*

3024

2024

1703

1402

1060

After vaccination:

(75% coverage)

     

Nr. of vaccinees

175925

115943

94354

80712

58724

Vaccination costs**

€14680941

€9675443

€7873841

€6735416

€4900518

Cases HZ

22512

12496

9201

6277

4299

Cases PHN

4222

2581

2071

1603

1257

Hospitalization

292

178

141

107

81

1 day visit hospital

966

563

426

294

188

Deaths

30.5

20.6

18.1

16.4

15.4

Direct costs*

€1832919

€1219724

€1082777

€902727

€760458

Indirect costs*

€541068

€0

€0

€0

€0

QALYs lost*

2671

1724

1350

1133

921

Prevented:

     

Cases HZ

4334

3017

1892

1352

471

Cases PHN

417

355

280

254

113

Hospitalization

28

27

21

20

9

1 day visit hospital

136

120

89

70

22

Deaths

0.2

0.3

0.5

1.2

1.1

Direct costs*

€384658

€307664

€223245

€197586

€87427

Indirect costs*

€700487

€0

€0

€0

€0

QALYs lost*

353

300

352

269

140

  1. * Costs are discounted with 4% and QALYs with 1.5%
  2. ** Vaccination costs are based on a vaccine price of €77, application costs of €4.80 per vaccination and coordination costs of €1.65 per vaccination